Username Password
PINA
WHO pauses trial of hydroxychloroquine in COVID-19 patients due to safety concerns
04:32 am GMT+12, 26/05/2020, Switzerland

The World Health Organisation has suspended testing the malaria drug hydroxychloroquine in COVID-19 patients due to safety concerns, WHO Director General Tedros Adhanom Ghebreyesus said on Monday.
 
Hydroxycholoroquine has been touted by Donald Trump and others as a possible treatment for the disease caused by the novel coronavirus. The U.S. President has said he was taking the drug to help prevent infection.
 
“The executive group has implemented a temporary pause of the hydroxychloroquine arm within the Solidarity trial while the safety data is reviewed by the data safety monitoring board,” Tedros told an online briefing.
 
He said the other arms of the trial - a major international initiative to hold clinical tests of potential treatments for the virus - were continuing.
 
The WHO has previously recommended against using hydroxychloroquine to treat or prevent coronavirus infections, except as part of clinical trials.
 
Dr Mike Ryan, head of the WHO emergencies programme, said the decision to suspend trials of hydroxychloroquine had been taken out of “an abundance of caution.

SOURCE: REUTERS/PACNEWS


News feature
There are no related media to this article.
Pacific Islands News Association
Who & What is PINA?
Membership
Member Countries
Media Freedom
Training
PINA Convention
Awards
Contact
Gallery
Forum
Events
Jobs
Classifieds
PACNEWS
Home
Regional
Feature
Business
Sports
Archives
Partners
Communications Initiative
International News Safety Institute (INSI)
UNDP PC
AusAID
NZAID
SPREP
ONOC
UNAIDS
Media Helping Media
Partners
PIFS
SPC
IFEX
UNESCO
AIBD
GFMD
SEAPA
WPFC
IFJ